Company record · AMGN · Biological Products, (No Diagnostic Substances)
Amgen
The principal financial officer who signed Amgen's latest annual report, the 10-K filed February 13, 2026, is Peter H. Griffith.
The record holds the CFO signature on Amgen's 10-K filed February 13, 2026 and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Peter H. Griffith |
| Title as printed | Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
| Basis | Verified February 13, 2026: the 10-K signature block (sec.gov) |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-02-1310-K signature
Peter H. Griffith signed the annual report as Executive Vice President and Chief Financial Officer (Principal Financial Officer)
10-K filed February 13, 2026 · sec.gov
“/s/ PETER H. GRIFFITH Peter H. Griffith Executive Vice President and Chief Financial Officer (Principal Financial Officer)”
Company
| Ticker | AMGN |
|---|---|
| SEC CIK | 0000318154 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-07 also names Peter H. Griffith alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-05-19, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.